# Study to Learn More About Safety of Aflibercept Injection in Japanese Patients With Neovascular Glaucoma (NVG)

> **NCT04519619** · — · RECRUITING · sponsor: **Bayer** · enrollment: 480 (estimated)

## Conditions studied

- Neovascular Glaucoma

## Interventions

- **DRUG:** Aflibercept (Eylea, BAY86-5321)

## Key facts

- **NCT ID:** NCT04519619
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2020-11-27
- **Primary completion:** 2027-06-30
- **Final completion:** 2028-06-30
- **Target enrollment:** 480 (ESTIMATED)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04519619

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04519619, "Study to Learn More About Safety of Aflibercept Injection in Japanese Patients With Neovascular Glaucoma (NVG)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04519619. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*